Table 1.
FDA-approved antiretroviral drugs or drug combinations that target RT
| Brand Name | Generic Name | Approval Date NRTIs | Notes |
|---|---|---|---|
| Retrovir | zidovudine, azidothymidine, ZDV | March 1987 | Generic form available |
| Videx | didanosine, dideoxyinosine, ddI | October 1991 | Generic form available |
| Hivid | zalcitabine, dideoxycytidine, ddC | June 1992 | No longer marketed due to serious adverse events |
| Zerit | stavudine, d4T | June 1994 | Use is being phased out due to long-term, irreversible side effects |
| Epivir | lamivudine, 3TC | November 1995 | Generic form available |
| Ziagen | abacavir sulfate, ABC | December 1998 | |
| Viread | tenofovir disoproxil fumarate, TDF | October 2001 | |
| Emtriva | emtricitabine, (−)-FTC | July 2003 | |
| NNRTIs | |||
| Viramune | nevirapine, NVP | June 1996 | |
| Rescriptor | delavirdine, DLV | April 1997 | Efficacy < NVP and EFV and is not recommended as part of initial therapy. Cross-resistance among the NNRTI class limits DLV use in second-line therapy. |
| Sustiva | efavirenz, EFV | September 1998 | |
| Intelence | etravirine, ETR | January 2008 | |
| Edurant | rilpivirine, RPV | May 2011 | |
| NRTI combinations | |||
| Combivir | 3TC+ZDV | September 1997 | |
| Trizivir | ABC+3TC+ZDV | November 2000 | |
| Epzicom | ABC+3TC | August 2004 | |
| Truvada | (−)-FTC+TDF | August 2004 | |
| NRTI/NNRTI combinations | |||
| Atripla | (−)-FTC+TDF+EFV | July 2006 | |
| Complera | (−)-FTC+TDF+RPV | August 2011 | |